Solid Biosciences Inc./$SLDB
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Solid Biosciences Inc.
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.
- Ticker
- $SLDB
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 121
- Headquarters
- Charlestown, United States
- Website
- www.solidbio.com
SLDB Metrics
BasicAdvanced
$665M
-
-$1.87
2.42
-
Price and volume
Market cap
$665M
Beta
2.42
52-week high
$11.45
52-week low
$3.79
Average daily volume
1.4M
Financial strength
Current ratio
13.823
Quick ratio
13.213
Long term debt to equity
0.048
Total debt to equity
0.054
Profitability
EBITDA (TTM)
-210.524
Management effectiveness
Return on assets (TTM)
-36.38%
Return on equity (TTM)
-65.50%
Valuation
Price to book
1.74
Price to tangible book (TTM)
1.74
Price to free cash flow (TTM)
-3.657
Free cash flow yield (TTM)
-27.35%
Free cash flow per share (TTM)
-1.696
Growth
Earnings per share change (TTM)
-25.74%
3-year earnings per share growth (CAGR)
-32.93%
What the Analysts think about SLDB
Analyst ratings (Buy, Hold, Sell) for Solid Biosciences Inc. stock.
Analyst projections of the future price of Solid Biosciences Inc. stock.
Bulls say / Bears say
SGT-003 has shown robust microdystrophin expression and sustained improvements in muscle-integrity markers in early biopsies. Published trial data also reported no drug-induced liver injury to the February 2026 cut-off, supporting the promise of its muscle-targeting approach. (Neuromuscular Disorders, Neuromuscular Disorders)
The company has started its randomised, placebo-controlled Phase 3 Duchenne trial, with the FDA aligned on its primary endpoint. It plans to discuss a possible accelerated-approval route with the FDA, creating a near-term regulatory milestone. (Solid Biosciences, Solid Biosciences)
Solid reported $377.7 million in cash and investments at the end of June 2026 and expects funding to last into mid-2028. That gives it time to support late-stage Duchenne work and develop other programmes without an immediate funding need. (Solid Biosciences)
The encouraging SGT-003 biopsy and biomarker results do not yet establish a meaningful improvement in patients’ daily function. Only three participants had reached the Day 360 biopsy time-point in the published data, and the company was still preparing to analyse 12-month clinical outcomes. (Neuromuscular Disorders, Solid Biosciences)
Two treatment-related serious adverse events had been reported among the 53 participants dosed in the SGT-003 trial by August 2026. Both had resolved, but the events show that safety remains a material risk for a systemic gene therapy. (StockTitan)
Solid remains loss-making: its second-quarter 2026 net loss was $54.8 million, up from $39.5 million a year earlier. It also raised cash through stock sales, including $60.8 million net from its ATM programme in the first half, which dilutes existing shareholders. (Solid Biosciences)
Data summarised monthly by Lightyear AI. Last updated on 31 Oct 2026.
SLDB Financial Performance
Revenues and expenses
SLDB Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing SLDB
Fund name | Fund size | $SLDB weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.04% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.04% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.02% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.